Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF) Head-To-Head Review

Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Agios Pharmaceuticals and Vectura Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	0	2	2	0	2.50
Vectura Group	0	0	0	0	N/A

Agios Pharmaceuticals presently has a consensus price target of $33.50, suggesting a potential upside of 5.31%. Given Agios Pharmaceuticals’ higher probable upside, equities analysts plainly believe Agios Pharmaceuticals is more favorable than Vectura Group.

Profitability

This table compares Agios Pharmaceuticals and Vectura Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-1,312.64%	-38.08%	-33.69%
Vectura Group	N/A	N/A	N/A

Risk & Volatility

Agios Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Vectura Group has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Valuation and Earnings

This table compares Agios Pharmaceuticals and Vectura Group’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$26.82 million	66.64	-$352.09 million	($6.34)	-5.02
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81

Vectura Group has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Summary

Vectura Group beats Agios Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.